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Renal and retinal effects  
of enalapril and losartan  
in type 1 diabetes
Mauer et al., N Engl J Med 2009; 361: 40–51
Since the initial demonstration that medications affecting the renin–
angiotensin axis improved kidney disease related to diabetes,1 tri-
als have tested these medications earlier and earlier in the disease 
course.2–4 Similarly, the Daily-Dose Consensus Interferon and Riba-
virin: Efficacy of Combined Therapy (DIRECT) trial5 reported that 
angiotensin receptor blockade reduced the rate of retinopathy devel-
opment in normotensive patients with type 1 diabetes who did not 
have abnormal albumin excretion rates or retinopathy. A multicenter 
trial by Mauer et al. sought to confirm the benefit to retinopathy seen 
in the DIRECT trial and extend the findings of prior studies on type 1 
diabetes and the progression of nephropathy. In separate arms, the 
authors examined the effect of enalapril and losartan, compared with 
placebo, on structural and functional changes within the kidneys and 
on development of retinopathy. Patients had type 1 diabetes mellitus 
and were normotensive, without abnormality in either creatinine or 
urinary albumin excretion. In 285 subjects, no difference was found 
between treatment arms for median albumin excretion rate, blood 
pressure, and glomerular filtration rate. Structural changes related to 
diabetes existed in the kidney biopsies of those enrolled at baseline 
before intervention. However, there was no difference in the progres-
sion or regression of these lesions across treatment arms. Surprisingly 
to the authors, enalapril did not change albumin excretion rate over 
5 years as compared with placebo; however, losartan significantly 
increased mean albumin excretion rate as compared with placebo. 
Both enalapril and losartan significantly reduced the progression of 
retinopathy by both moderate and severe definitions.
The fact that the Renin–Angiotensin System Study (RASS) was 
similar to DIRECT in finding a benefit in retinopathy confirms 
that the lack of benefit within the kidney is not related to decreased 
power or other causes of a type II statistical error. While research 
continues to examine whether the use of these medications is war-
ranted in the prevention of retinopathy, their use in the prevention 
of albuminuria and structural changes within the kidneys of type 1 
diabetics is not.
Lynda Szczech
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Chronic increases  
in circulating prorenin
Mercure et al., Hypertension 2009; 53: 1062–1069; doi:10.1161/
HYPERTENSIONAHA.108.115444
Renin is synthesized as a precursor, prorenin, a portion of which is 
converted to active renin by the proteolytic removal of an amino-
terminal segment before its secretion by the renal juxtaglomerular 
cells. Prorenin is also present in the blood plasma at levels 5 to 10 
times those of renin and is produced not only by the kidney but also 
by other tissues. Prorenin has less than 1% of renin’s enzymatic activ-
ity, but it appears to contribute to local angiotensin generation as it 
acquires enzymatic activity on binding to the (pro)renin receptor. In 
addition, both prorenin and renin can trigger intracellular mitogen-
activated protein kinase activity by binding to this receptor. Prorenin 
levels increase with age; in diabetic patients, it has been postulated 
that elevated prorenin levels may cause disease. To test this, Mer-
cure et al. generated transgenic mice with selective increases (13- to 
66-fold) in circulating native or active site–mutated prorenin. They 
found that systolic blood pressure was either unchanged or increased 
(+25 mm Hg) in mice expressing native prorenin, whereas the mice 
expressing active site–mutated prorenin showed no change. The kid-
neys from the most highly prorenin-expressing lines revealed no 
evidence of injury but did show a slight increase in the urine content 
of albumin. Renal glomerular sclerosis did not increase in any of the 
transgenic animals tested, even in 18-month-old mice (Figure). In 
addition, although some evidence of cardiac hypertrophy was seen 
in the hypertensive animals, there was no increase in cardiac fibrosis. 
These results suggest that the primary consequence of chronic eleva-
tions in circulating prorenin is an increase in blood pressure, which 
does not support a role for prorenin as the primary causative agent 
in cardiac fibrosis or renal glomerular injury. 
Juan Oliver
A mouse model of renal carcinoma
Morris and McClatchey, Proc Natl Acad Sci USA 2009; 106: 9767–9772; 
doi:10.1073/pnas.0902031106
Renal-cell carcinomas (RCCs), which derive from renal tubule epi-
thelial cells, are by far the most frequent kidney tumors. While most 
RCCs are sporadic, a few hereditary syndromes are associated with 
RCC. Somatic mutations in the genes associated with these syn-
dromes have been identified in sporadic RCC, but a surprisingly 
low number of recurrent genetic alterations have been identified in 
RCC patient samples, and only three genes were found mutated at 
a frequency greater than 4%: VHL, 42%; CDKN2A, 12%; and KIT, 
8%. That the homozygous mutation of the neurofibromatosis type 2 
(NF2) tumor suppressor gene was identified in approximately 2% of 
Tissue effects of chronic hyper-proreninemia. In 18-month-old male control 
and transgenic mice, there was no increase in glomerulosclerosis (top) or 
cardiac fibrosis (bottom) in the animals with elevated levels of prorenin.
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RCC patients was considered significant by Morris and McClatchey, 
especially in light of their previous work showing that the Nf2 tumor 
suppressor Merlin is a critical regulator of epidermal growth factor 
receptor (EGFR). It has long been known that EGFR and its ligands, 
EGF and transforming growth factor-α, are frequently overexpressed 
in many forms of RCC. In a variety of conditions, the Nf2 tumor sup-
pressor Merlin coordinates the inhibition of EGFR signaling with the 
establishment of stable adherens junctions, thus mediating contact-
dependent inhibition of proliferation. Morris and McClatchey thus 
hypothesized that Nf2 mutation could generate renal tubular epi-
thelial tumors. They first generated mice with a targeted deletion of 
Nf2 in the proximal convoluted tubule using a Villin-Cre transgene 
and found that all these mice developed intratubular neoplasia that 
progressed to invasive carcinoma (Figure, left panels). To ascertain 
whether these renal tubule tumors derived from a developmentally 
and/or regionally specific cell population, they deleted Nf2 in the 
collecting duct and the thick ascending loop of Henle of the adult 
kidney using the interferon-α-inducible Mx1-Cre transgene. These 
mice also developed lumen-filling renal tubule neoplasia (Figure, 
right panels). Interestingly, early lesions exhibited hyperactivation 
of EGFR signaling, altered solubility of adherens junctions compo-
nents, and loss of epithelial polarity. Renal cortical epithelial cells 
derived from either early or late lesions formed malignant tumors 
upon subcutaneous injection into immune-compromised mice. 
Hence, targeted loss of the Nf2 tumor suppressor in renal tubule epi-
thelial cells gives rise to tumor development with 100% penetrance. 
These studies give further support to the role of EGFR signaling in 
RCC, suggesting that Nf2 deficiency may be an important contrib-
uting factor in generation of these tumors and may provide a very 
useful model to study renal neoplasia.
Juan Oliver
ABCG2 is a renal urate transporter 
with a common functional 
polymorphism causing gout
Woodward et al., Proc Natl Acad Sci USA 2009; 106: 10338–10342; doi:10.1073/
pnas.0901249106
Genome-wide association studies (GWASs) have successfully identi-
fied common single-nucleotide polymorphisms (SNPs) associated 
with a wide variety of complex diseases, including hypertension and 
chronic kidney disease. However, with rare exceptions, these studies 
do not address gene function or establish causality of the disease-
associated SNP. Serum urate levels are highly heritable, and the main 
cause of elevated plasma urate levels is decreased renal urate excre-
tion. Several renal urate transporters have been characterized, but 
their role in human disease is mostly unclear. Furthermore, despite 
much work and because of its complexity, renal urate transport is 
still poorly understood. In a GWAS of serum urate levels, multi-
ple SNPs associated with urate levels and prevalence of gout were 
recently identified in a genomic region on chromosome 4 containing 
the ATP-binding cassette, subfamily G, member 2 (ABCG2) gene. 
ABCG2 was initially identified as a multidrug-resistance protein and 
was found to transport a wide range of structurally and function-
ally diverse substrates. However, the physiological substrate and the 
role(s) of ABCG2 in vivo have remained elusive. In a recent study, 
Woodward et al. expressed human ABCG2 in Xenopus oocytes. They 
found that human ATP-binding cassette, subfamily G, 2 (ABCG2) 
is a hitherto unknown urate efflux transporter. Urate accumulation 
was markedly decreased in oocytes expressing ABCG2, and these 
oocytes had lower urate concentrations than oocytes expressing 
the known urate efflux transporter MRP4. In addition, the reduced 
urate accumulation in ABCG2-expressing oocytes was absent in the 
presence of a specific ABCG2 inhibitor, or after introduction of a 
mutation in ABCG2 that is known to disrupt its function. To analyze 
the urate-transport capacity of endogenous ABCG2 in polarized 
renal epithelia, the authors measured urate accumulation in LLC-
PK1 cells. Inhibition of ABCG2 caused a significant impairment 
of urate export from the cells and higher intracellular urate accu-
mulation. In polarized LLC-PK1 cells, ABCG2 was localized to the 
apical brush border membrane (Figure), which is consistent with 
the recent demonstration of ABCG2 in the brush border of human 
proximal tubule cells. To test whether the most significant SNP of 
the GWAS of serum urate levels (rs2231142 in exon 5 of ABCG2) 
was not only statistically associated but causally related to elevated 
urate levels, the authors introduced the mutation Q141K, encoded 
by the rs2231142 T allele, by site-directed mutagenesis. They found 
that Q141K-expressing oocytes had markedly reduced urate trans-
port rates and decreased urate efflux across a range of intracellular 
urate concentrations. Hence, Q141K was shown to be a causal loss-
of-function variant. Analysis of subjects from the GWAS further 
supported causality of rs2231142. These findings are of consider-
able clinical interest because of the high prevalence of the Q141K 
mutation in individuals of European and Asian ancestry. ABCG2 
therefore represents a potential drug target.
Juan Oliver 
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All Vil-Cre;Nf2lox/lox mice (left panels) developed small intratubular 
neoplastic growths that grew to large tumors by 3 months and progressed 
to invasive carcinomas. This kidney phenotype was recapitulated in 
inducible Mx1-Cre;Nf2lox/lox mice (right panels).
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ABCG2 (green) detected in the apical brush border membrane of LLC-PK1 
cells. Nuclear DAPI stain (blue).
